Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial

Andishe Attarbaschi^#¹, Georg Mann^#², Martin Zimmermann^#³, Peter Bader⁴, Elena Barisone⁵, Giuseppe Basso⁶, Andrea Biondi⁷, Gunnar Cario⁸, Gianni Cazzaniga⁷, Antonella Colombini⁷, Christian Flotho⁹, Michaela Kuhlen¹⁰, Peter Lang¹¹, Melchior Lauten¹², Christin Linderkamp³, Franco Locatelli^{13

14}, Luca Lo Nigro¹⁵, Anja Möricke⁸, Felix Niggli¹⁶, Renate Panzer-Grümayer², Rosanna Parasole¹⁷, Christina Peters², Maria Caterina Putti¹⁸, Carmelo Rizzari⁷, Meinolf Suttorp¹⁹, Maria Grazia Valsecchi²⁰, Valentino Conter^#⁷, Martin Schrappe^#⁸; on behalf of the AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica & Berlin-Frankfurt-Münster) Study Group

Affiliations

¹ Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. andishe.attarbaschi@stanna.at.
² Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
³ Department of Pediatric Hematology and Oncology, Children's Hospital, Medical School Hannover, Hannover, Germany.
⁴ Department of Children and Adolescent Medicine, Children's Hospital, Goethe University, Frankfurt, Germany.
⁵ Pediatric Onco-Hematology, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy.
⁶ Italian Institute for Genomic Medicine, Turin, Italy.
⁷ Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation/ASST Monza, Monza, Italy.
⁸ Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
⁹ Department of Pediatric Hematology and Oncology, Children's Hospital, Albert Ludwigs University, Freiburg, Germany.
¹⁰ University Children's Hospital Augsburg, Swabian Children's Cancer Center, Augsburg, Germany.
¹¹ Department of Pediatric Hematology and Oncology, Children's Hospital, Eberhard Karls University, Tübingen, Germany.
¹² Department of Pediatric and Adolescent Medicine, Children's Hospital, University of Lübeck, Lübeck, Germany.
¹³ Department of Pediatric Hematology-Oncology, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.
¹⁴ Department of Pediatrics, Sapienza, University of Rome, Rome, Italy.
¹⁵ Center of Pediatric Hematology Oncology, Azienda Policlinico-OVE, Catania, Italy.
¹⁶ Department of Pediatric Oncology, University Children's Hospital, Zürich, Switzerland.
¹⁷ Department of Pediatric Hemato-Oncology, A.O.R.N. Santobono-Pausilipon, Naples, Italy.
¹⁸ Department of Woman and Child Health, Clinic of Pediatric Haematology-Oncology, University of Padova, Padova, Italy.
¹⁹ Department of Pediatrics, Pediatric Hemato-Oncology Unit, Children's Hospital, University Hospital "Carl Gustav Carus", Dresden, Germany.
²⁰ Center of Biostatistics for Clinical Epidemiology, Department of Health Science, University of Milano-Bicocca, Milano, Italy.

^# Contributed equally.

PMID: 31806872
DOI: 10.1038/s41375-019-0670-y

Randomized Controlled Trial

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial

Andishe Attarbaschi et al. Leukemia. 2020 Jun.

. 2020 Jun;34(6):1694-1700.

doi: 10.1038/s41375-019-0670-y. Epub 2019 Dec 5.

Authors

Affiliations

¹ Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. andishe.attarbaschi@stanna.at.
² Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
³ Department of Pediatric Hematology and Oncology, Children's Hospital, Medical School Hannover, Hannover, Germany.
⁴ Department of Children and Adolescent Medicine, Children's Hospital, Goethe University, Frankfurt, Germany.
⁵ Pediatric Onco-Hematology, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy.
⁶ Italian Institute for Genomic Medicine, Turin, Italy.
⁷ Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation/ASST Monza, Monza, Italy.
⁸ Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
⁹ Department of Pediatric Hematology and Oncology, Children's Hospital, Albert Ludwigs University, Freiburg, Germany.
¹⁰ University Children's Hospital Augsburg, Swabian Children's Cancer Center, Augsburg, Germany.
¹¹ Department of Pediatric Hematology and Oncology, Children's Hospital, Eberhard Karls University, Tübingen, Germany.
¹² Department of Pediatric and Adolescent Medicine, Children's Hospital, University of Lübeck, Lübeck, Germany.
¹³ Department of Pediatric Hematology-Oncology, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.
¹⁴ Department of Pediatrics, Sapienza, University of Rome, Rome, Italy.
¹⁵ Center of Pediatric Hematology Oncology, Azienda Policlinico-OVE, Catania, Italy.
¹⁶ Department of Pediatric Oncology, University Children's Hospital, Zürich, Switzerland.
¹⁷ Department of Pediatric Hemato-Oncology, A.O.R.N. Santobono-Pausilipon, Naples, Italy.
¹⁸ Department of Woman and Child Health, Clinic of Pediatric Haematology-Oncology, University of Padova, Padova, Italy.
¹⁹ Department of Pediatrics, Pediatric Hemato-Oncology Unit, Children's Hospital, University Hospital "Carl Gustav Carus", Dresden, Germany.
²⁰ Center of Biostatistics for Clinical Epidemiology, Department of Health Science, University of Milano-Bicocca, Milano, Italy.

^# Contributed equally.

PMID: 31806872
DOI: 10.1038/s41375-019-0670-y

No abstract available

PubMed Disclaimer

References

1. Arico M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood. 2002;100:420–6. - DOI
1. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206–14. - DOI
1. Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123:1470–8. - DOI
1. Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia. 2013;27:1497–503. - DOI
1. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N. Engl J Med. 1998;338:1663–71. - DOI

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial

Affiliations

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial

Authors

Affiliations

References

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

Full Text Sources